6,4'-Dimethoxyflavone

6,4'-Dimethoxyflavone

SCHEMBL4281291

COc1ccc(-c2cc(=O)c3cc(OC)ccc3o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 1.00
TP53 P04637 6/20 1.00
CYP3A4 P08684 5/20 1.00
KDM4E B2RXH2 4/20 1.00
ALDH1A1 P00352 4/20 1.00
HPGD P15428 4/20 1.00
NPC1 O15118 3/20 1.00
RAB9A P51151 3/20 1.00
HSD17B10 Q99714 3/20 1.00
NFKB1 P19838 2/20 1.00
NFKB2 Q00653 2/20 1.00
RELA Q04206 2/20 1.00
LMNA P02545 2/20 1.00
THRB P10828 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
RXFP1 Q9HBX9 1/20 1.00
MEN1 O00255 4/20 0.84
KMT2A Q03164 4/20 0.84
CYP2C9 P11712 3/20 0.84
CYP2C19 P33261 3/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
6,4'-Dimethoxyflavone SCHEMBL29478471 1.00 MAPT (1.00) MAPTTP53CYP3A4KDM4EALDH1A1
SCHEMBL31238310 0.96 MAPT (0.91) MAPTTP53CYP3A4KDM4EALDH1A1
SCHEMBL12941864 0.91 MAPT (0.84) MAPTTP53CYP3A4KDM4EALDH1A1
SCHEMBL4650062 0.91 MAPT (1.00) MAPTTP53CYP3A4KDM4EALDH1A1
SCHEMBL31675778 0.91 MAPT (1.00) MAPTTP53CYP3A4KDM4EALDH1A1
SCHEMBL4983269 0.91 MAPT (0.84) MAPTTP53CYP3A4KDM4EALDH1A1
6-Methoxyflavone SCHEMBL30799564 0.91 ABCB1 (1.00) MAPTTP53CYP3A4KDM4EALDH1A1
6-Methoxyflavone SCHEMBL312059 0.91 ABCB1 (1.00) MAPTTP53CYP3A4KDM4EALDH1A1
6-Methoxyflavone SCHEMBL28930176 0.91 ABCB1 (1.00) MAPTTP53CYP3A4KDM4EALDH1A1
SCHEMBL535143 0.90 KCNA5 (1.00) MAPTTP53CYP3A4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282871-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TIANJIN LIPOGEN TECH CO LTD (CN) 2025-09-11 US claimed
US-20240285755-A1 Adjuvants GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-08-29 US claimed
US-20240277751-A1 CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-08-22 US claimed
EP-4346894-A1 ADJUVANTS GlaxoSmithKline Biologicals S.A. (BE) 2024-04-10 EP claimed
EP-4342492-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF Tianjin Lipogen Technology Co., Ltd (CN) 2024-03-27 EP claimed
CN-117396222-A Pharmaceutical combination and use thereof 天津立博美华基因科技有限责任公司 2024-01-12 CN claimed
EP-4228657-A1 CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE The Regents Of The University Of Michigan (US) 2023-08-23 EP claimed
CN-116390764-A Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses 密歇根大学董事会 2023-07-04 CN claimed
US-20220387470-A1 METHODS OF MODULATING IMMUNE ACTIVITY FLAGSHIP PIONEERING INNOVATIONS V, INC. 2022-12-08 US claimed
WO-2022248353-A1 ADJUVANTS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-12-01 WO claimed
US-20180311206-A1 USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION UNIV DREXEL (US) 2018-11-01 US claimed
US-20170281589-A1 USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION UNIV DREXEL (US) 2017-10-05 US claimed
US-9642830-B2 Use of sting agonists to treat hepatitis B virus infection DREXEL UNIVERSITY (US) 2017-05-09 US claimed
US-20160256434-A1 USE OF STING AGONISTS TO TREAT HEPATITIS B VIRUS INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-08 US claimed
EP-3060056-A2 USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION Drexel University (US) 2016-08-31 EP claimed
WO-2015061294-A2 USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A/ (US) 2015-04-30 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387470-A1 METHODS OF MODULATING IMMUNE ACTIVITY STING1, IRF3, CGAS MAPT 4883/4885TP53 1117/4885CYP3A4 4530/4885
US-20240285755-A1 Adjuvants STING1, TLR3, TLR9 MAPT 4240/4885TP53 553/4885CYP3A4 4646/4885
US-20240277751-A1 CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE STING1, CGAS, IRF3 MAPT 3811/4885TP53 388/4885CYP3A4 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.